EF Hutton Initiates Coverage On Indonesia Energy Corp with Buy Rating, Announces Price Target of $11
EF Hutton analyst Ben Piggott initiates coverage on Indonesia Energy Corp (AMEX:INDO) with a Buy rating and announces Price Target of $11.
William Blair Initiates Coverage On POINT Biopharma Global with Outperform Rating
William Blair analyst Andy Hsieh initiates coverage on POINT Biopharma Global (NASDAQ:PNT) with a Outperform rating.
Needham Initiates Coverage On Definitive Healthcare with Buy Rating, Announces Price Target of $30
Needham analyst Ryan MacDonald initiates coverage on Definitive Healthcare (NASDAQ:DH) with a Buy rating and announces Price Target of $30.
Oppenheimer Initiates Coverage On Portman Ridge Finance with Perform Rating, Announces Price Target of $26
Oppenheimer analyst Mitchel Penn initiates coverage on Portman Ridge Finance (NASDAQ:PTMN) with a Perform rating and announces Price Target of $26.
Wolfe Research Initiates Coverage On Teleflex with Outperform Rating
Wolfe Research analyst Mike Polark initiates coverage on Teleflex (NYSE:TFX) with a Outperform rating.
Wolfe Research Initiates Coverage On Medtronic with Underperform Rating
Wolfe Research analyst Mike Polark initiates coverage on Medtronic (NYSE:MDT) with a Underperform rating.
JP Morgan Initiates Coverage On Avid Technology with Overweight Rating, Announces Price Target of $33
JP Morgan analyst Paul Chung initiates coverage on Avid Technology (NASDAQ:AVID) with a Overweight rating and announces Price Target of $33.
HC Wainwright Finds ‘Synergies In Treatment’ For This Bipolar-Focused Stock
HC Wainwright initiated coverage on NRx Pharmaceuticals Inc (NASDAQ:NRXP) with a Buying rating and a price target of $2. Earlier today, the FDA…
HC Wainwright Sees Over 300% Upside In This Cancer-Focused Stock
HC Wainwright has initiated Theseus Pharmaceuticals Inc (NASDAQ:THRX) with a Buy rating and a price target of $22 (310% upside). The analysts see…
Citigroup Initiates Coverage On Symbotic with Buy Rating, Announces Price Target of $15
Citigroup analyst Andrew Kaplowitz initiates coverage on Symbotic (NASDAQ:SYM) with a Buy rating and announces Price Target of $15.